Abstract
The potential utility of wastewater-based epidemiology as an early warning tool has been explored widely across the globe during the current COVID-19 pandemic. Methods to detect the presence of SARS-CoV-2 RNA in wastewater were developed early in the pandemic, and extensive work has been conducted to evaluate the relationship between viral concentration and COVID-19 case numbers at the catchment areas of sewage treatment works (STWs) over time. However, no attempt has been made to develop a model that predicts wastewater concentration at fine spatio-temporal resolutions covering an entire country, a necessary step towards using wastewater monitoring for the early detection of local outbreaks.
We consider weekly averages of flow-normalised viral concentration, reported as the number of SARS-CoV-2 N1 gene copies per litre (gc/L) of wastewater available at 303 STWs over the period between 1 June 2021 and 30 March 2022. We specify a spatially continuous statistical model that quantifies the relationship between weekly viral concentration and a collection of covariates covering socio-demographics, land cover and virus-associated genomic characteristics at STW catchment areas while accounting for spatial and temporal correlation.
We evaluate the model’s predictive performance at the catchment level through 10-fold cross-validation. We predict the weekly viral concentration at the population-weighted centroid of the 32,844 lower super output areas (LSOAs) in England, then aggregate these LSOA predictions to the Lower Tier Local Authority level (LTLA), a geography that is more relevant to public health policy-making. We also use the model outputs to quantify the probability of local changes of direction (increases or decreases) in viral concentration over short periods (e.g. two consecutive weeks).
The proposed statistical framework is able to predict SARS-CoV-2 viral concentration in wastewater at high spatio-temporal resolution across England. Additionally, the probabilistic quantification of local changes can be used as an early warning tool for public health surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The United Kingdom Government (Department of Health and Social Care) funded the sampling, testing, and data analysis of wastewater in England via the UK Health Security Agency Environmental Monitoring for Health Protection National Surveillance programme. SR is supported by MRC programme grant MC_UU_00002/10; The Alan Turing Institute grant: TU/B/000092; EPSRC Bayes4Health programme grant: EP/R018561/1. GN and CH acknowledge support from the Medical Research Council Programme Leaders award MC_UP_A390_1107. CH acknowledges support from The Alan Turing Institute, Health Data Research, U.K., and the U.K.Engineering and Physical Sciences Research Council through the Bayes4Health programme grant. MB acknowledges partial support from the MRC Centre for Environment and Health, which is currently funded by the Medical Research Council (MR/S019669/1). FT acknowledges support from the MRC grant MR/V028367/1, the HDR-9006, the ESRC ES/S007393/1 and the Wales COVID-19 Evidence Centre. Infrastructure support for the Department of Epidemiology and Biostatistics is also provided by the NIHR Imperial BRC. Authors in The Alan Turing Institute and Royal Statistical Society Statistical Modelling and Machine Learning Laboratory gratefully acknowledge funding from Data, Analytics and Surveillance Group, a part of the UKHSA. This work was funded by The Department for Health and Social Care with in-kind support from The Alan Turing Institute and The Royal Statistical Society.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/gqlNU/publicWW/